The Oncology Institute Inc. Common Stock Q3 2025 Earnings Recap

TOI Q3 2025 November 14, 2025

Get alerts when TOI reports next quarter

The Oncology Institute delivered strong third quarter results, achieving $137 million in revenue—up 23% year-over-year—while marking its first month of adjusted EBITDA profitability as a public company.

Earnings Per Share Miss

$-0.14 vs $-0.12 est.

-16.7% surprise

Revenue Miss

136564000 vs 139780500 est.

-2.3% surprise

Market Reaction

1-Day +28.9%

5-Day +6.17%

30-Day +9.74%

See TOI alongside your other holdings

Add to your portfolio — free

Key Takeaways

Pharmacy business surged 42% year-over-year, driving significant revenue growth.
Achieved a $4.7 million improvement in adjusted EBITDA loss compared to Q3 2024, with expectations to reach overall profitability in Q4.
Expanded partnership with Elevance Health, doubling the Medicare Advantage lives under capitation in under a year.
Launched AI initiatives to enhance operational efficiency, potentially saving $2 million in operating expenses.
Despite a recent cybersecurity incident affecting billing, operations remained largely unaffected, with strong cash reserves projected for Q4 and 2026.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TOI on AllInvestView.